Yellow fever disease in a renal transplant recipient: Case report and literature review
- PMID: 31344763
- DOI: 10.1111/tid.13151
Yellow fever disease in a renal transplant recipient: Case report and literature review
Abstract
Yellow fever (YF) is a viral disease, with clinical presentation among immunosuppressed patients not fully understood. YF vaccination (YFV), a live vaccine, is contraindicated in patients receiving immunosuppressive treatment due to the risk of developing the disease after vaccination. We report a case of a 50-year-old male recipient who presented wild-type YF five years after a deceased donor kidney transplant. He lived in a YF endemic area and inadvertently received YFV. One day after YFV, the patient presented nausea, vomiting, fever, diarrhea, polyarthralgia, thrombocytopenia, and increased levels of liver function enzymes. The serological test was compatible with YF disease, and quantitative viral load confirmed the diagnosis of wild-type YF. The patient received supportive care for twelve days, with hospital discharge in good clinical condition and stable renal function. One month after discharge, the patient developed de novo donor-specific anti-HLA antibodies (DSA) and histological evidence of endothelial lesion, with a diagnosis of acute antibody-mediated rejection (AMR), treated with plasmapheresis and human IVIg therapy. Six months after therapy, he presented normal renal function with a reduction of DSA MFI. In the reported case, we observed a clinical wild-type YF diagnosed even after YF vaccine administration, with good clinical outcome. De novo DSA and AMR occurred after the recovering of disease, with an adequate response to therapy and preserved allograft function. We reviewed the published literature on YF and YFV in solid organ transplantation.
Keywords: HLA antigens; antibody-producing cells; arbovirus infections; graft rejection; immunosuppression; plasmapheresis.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Goldani LZ. Yellow fever outbreak in Brazil, 2017. Brazilian J Infect Dis. 2017;21(2):123-124.
-
- Sicre de Fontbrune F, Arnaud C, Cheminant M, et al. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy. J Infect Dis. 2018;217(3):494-497.
-
- Saúde BMdSSdAà. Febre amarela: guia para profissionais de saúde TT - Yellow fever: a guide for health professionals. 2017:59.
-
- Löbermann M, Boršo D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212-218.
-
- Wyplosz B, Burdet C, François H, et al. Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation. Am J Transplant. 2013;13(9):2458-2461.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
